Calithera Biosciences, Inc.: directors' dealings · United States · SEC (Form 4)

About Calithera Biosciences, Inc.

Calithera Biosciences, Inc. is a U.S.-based biopharmaceutical company that was historically listed on the NASDAQ market in the United States (United States). The company was founded in 2010 in the San Francisco / South San Francisco biotech ecosystem and built its strategy around targeted therapies designed to interfere with tumor metabolism and tumor immunology. Its scientific thesis focused on starving cancer cells of critical survival pathways while potentially enhancing immune-cell activity, a common but highly competitive frontier in oncology drug development. Calithera’s headquarters were located in South San Francisco, California, reflecting its roots in one of the main U.S. life-science clusters. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1496671/000095017023011047/cala-20221231.htm?utm_source=openai)) Operationally, Calithera was best described as a clinical-stage biotech rather than a commercial pharma company. Its business model relied on discovering and advancing small-molecule drug candidates aimed at metabolic and immunologic cancer targets. That placed the company in a niche segment of oncology where scientific differentiation matters, but where execution risk is high and the competitive set is broad: large pharmaceutical companies, better-capitalized biotech peers, and platform-driven developers all compete for the same clinical and partnering opportunities. As a result, the company’s market position was never that of a scale leader; it was a specialized, research-intensive developer whose value depended on clinical data, financing access, and regulatory progress. ([linkedin.com](https://www.linkedin.com/company/calithera-biosciences?utm_source=openai)) The most important recent development is that Calithera effectively ceased operating as a going concern. In January 2023, the board approved a plan of complete liquidation and dissolution, and the company announced that it was discontinuing all clinical development programs and reducing its workforce. Shortly thereafter, Nasdaq notified Calithera that it viewed the company as a “public shell,” and trading of the common stock was suspended, with the listing subsequently removed. For investors, that is the defining context: CALA is no longer a normal operating biotech equity story, but rather a liquidation-case security with highly event-driven economics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1496671/000119312523014684/d181884d8k.htm?utm_source=openai)) From an international equity-analytics perspective, the company remains relevant mainly for historical reference, SEC filing analysis, and insider-transaction monitoring through Form 4 disclosures. Any reading of Calithera today should therefore be framed around residual asset monetization, dissolution mechanics, and potential distribution outcomes rather than product revenue or pipeline growth. In short, Calithera is a U.S. healthcare name whose investment case has shifted from oncology innovation to corporate wind-down and value realization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1496671/000119312523014684/d181884d8k.htm?utm_source=openai))